...
首页> 外文期刊>Cancer Communications >Pathologic response after preoperative therapy predicts prognosis of Chinese colorectal cancer patients with liver metastases
【24h】

Pathologic response after preoperative therapy predicts prognosis of Chinese colorectal cancer patients with liver metastases

机译:术前治疗后的病理反应可预测中国大肠癌肝转移患者的预后

获取原文
           

摘要

Pathologic response is evaluated according to the extent of tumor regression and is used to estimate the efficacy of preoperative treatment. Several studies have reported the association between the pathologic response and clinical outcomes of colorectal cancer patients with liver metastases who underwent hepatectomy. However, to date, no data from Chinese patients have been reported. In this study, we aimed to evaluate the association between the pathologic response to pre-hepatectomy chemotherapy and prognosis in a cohort of Chinese patients. In this retrospective study, we analyzed the data of 380 liver metastases in 159 patients. The pathologic response was evaluated according to the tumor regression grade (TRG). The prognostic role of pathologic response in recurrence-free survival (RFS) and overall survival (OS) was assessed using Kaplan–Meier curves with the log-rank test and multivariate Cox models. Factors that had potential influence on pathologic response were also analyzed using multivariate logistic regression and Kruskal–Wallis/Mann–Whitney U tests. Patients whose tumors achieved pathologic response after preoperative chemotherapy had significant longer RFS and OS than patients whose tumor had no pathologic response to chemotherapy (median RFS: 9.9 vs. 6.5 months, P = 0.009; median OS: 40.7 vs. 28.1 months, P = 0.040). Multivariate logistic regression and Kruskal–Wallis/Mann–Whitney U tests showed that metastases with small diameter, metastases from the left-side primary tumors, and metastases from patients receiving long-duration chemotherapy had higher pathologic response rates than their control metastases (all P  0.05). A decrease in the serum carcinoembryonic antigen (CEA) level after preoperative chemotherapy predicted an increased pathologic response rate (P  0.05). Although the application of targeted therapy did not significantly influence TRG scores of all cases of metastases, the addition of cetuximab to chemotherapy resulted in a higher pathologic response rate when combined with irinotecan-based regimens rather than with oxaliplatin-based regimens. We found that the evaluation of pathologic response may predict the prognosis of Chinese colorectal cancer patients with liver metastases after preoperative chemotherapy. Small tumor diameter, long-duration chemotherapy, left primary tumor, and decreased serum CEA level after chemotherapy are associated with increased pathologic response rates.
机译:根据肿瘤消退的程度评估病理反应,并用于评估术前治疗的疗效。几项研究报告了接受肝切除的结直肠癌伴肝转移的大肠癌患者的病理反应与临床结局之间的关系。但是,迄今为止,尚无中国患者的数据报道。在这项研究中,我们旨在评估一组中国患者对肝切除术前化疗的病理反应与预后之间的关系。在这项回顾性研究中,我们分析了159例患者中380例肝转移的数据。根据肿瘤消退等级(TRG)评估病理反应。使用对数秩检验和多变量Cox模型的Kaplan-Meier曲线评估了病理反应在无复发生存期(RFS)和总生存期(OS)中的预后作用。还使用多元逻辑回归和Kruskal–Wallis / Mann–Whitney U检验分析了对病理反应有潜在影响的因素。肿瘤在术前化疗后达到病理反应的患者的RFS和OS明显长于对化疗无病理反应的患者(RFS中位数:9.9 vs. 6.5个月,P = 0.009;中位OS:40.7 vs. 28.1个月,P = 0.040)。多元逻辑回归和Kruskal–Wallis / Mann–Whitney U检验显示,直径较小的转移灶,左侧原发肿瘤的转移灶以及长期接受化疗的患者的转移灶的病理反应率均高于对照转移灶(所有P <0.05)。术前化疗后血清癌胚抗原(CEA)水平降低预示病理反应率升高(P <0.05)。尽管靶向治疗的应用并没有显着影响所有转移病例的TRG评分,但是与基于伊立替康的治疗方案而非基于奥沙利铂的治疗方案联合使用西妥昔单抗化疗会导致更高的病理学应答率。我们发现病理反应的评估可以预测术前化疗后中国结直肠癌肝转移患者的预后。小肿瘤直径,长期化疗,左原发肿瘤和化疗后血清CEA水平降低与病理反应率增加相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号